Praxistipps Migräneprophylaxe

Patientinnen und Patienten mit häufigen und schweren Migräneattacken benötigen eine medikamentöse und nicht medikamentöse Migräneprophylaxe. Trotz einer Vielzahl kontrollierter randomisierter Studien, die unterschiedliche Ansätze zur Migräneprophylaxe untersuchen, bleiben im klinischen Alltag viele Fragen zum Management von Migränepatienten offen. Daher hat die Internationale Kopfschmerzgesellschaft (IHS) entschieden, für diese Fragen Praxisempfehlungen, beruhend auf Beobachtungsstudien und Expertenkonsens, zu formulieren.

Abstract

Patients experiencing frequent and severe migraine attacks require both drug and non-drug prophylactic treatments for migraines. Despite the large number of randomised controlled trials investigating different approaches to migraine prophylaxis, many questions regarding the management of migraine patients remain unanswered in everyday clinical practice. The International Headache Society (IHS) has therefore decided to formulate practical recommendations based on observational studies and expert consensus to address these questions.

Kernaussagen

• Indikation: Eine medikamentöse Prophylaxe ist angezeigt bei ≥ 4 Migränetagen pro Monat und relevanter Beeinträchtigung der Lebensqualität.

• Ziel: Therapieerfolg ist definiert als ≥ 50% Reduktion der Migränetage (episodisch) bzw. ≥ 30% (chronisch) oder eine relevante subjektive Verbesserung.

• Therapieentscheidung: Erfolgt gemeinsam mit dem Patienten – individuelle Präferenzen, Erwartungen und Komorbiditäten müssen berücksichtigt werden.

• CGRP-Antikörper: wirken schneller und sind oft besser verträglich als klassische orale Prophylaktika; auch Spätresponder sind möglich.

• Therapiebeurteilung: üblicherweise nach 3 Monaten, bei quartalsweiser Gabe nach 6 Monaten – ggf. längere Beobachtung sinnvoll.

• Therapiewechsel: Bei Nichtansprechen kann ein Wechsel innerhalb der Substanzklassen (z. B. CGRP-Antikörper ↔ Gepante) wirksam sein.

• Kombinationen: Kombinationstherapien sind möglich, aber derzeit nicht standardisiert oder ausreichend untersucht.

• Dauer: mindestens 6–12 Monate; bei chronischer Migräne oder Komorbiditäten auch länger – regelmäßige Reevaluation empfohlen.

• Besondere Gruppen: Schwangerschaft, Stillzeit, Kinder, ältere Patienten und Komorbiditäten erfordern individualisierte Therapieansätze.

Schlüsselwörter

Migräneprophylaxe - CGRP-Antikörper - Komorbiditäten - Migräneattacke - chronische Migräne

Keywords

migraine prophylaxis - CGRP antibody - comorbidities - chronic migraine

Publication History

Article published online:
23 February 2026

• Literatur

• 1 Diener HC, Förderreuther S, Kropp P. et al. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, DGN und DMKG, in: Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie. Accessed June 27, 2025 at: https://www.dgn.org/leitlinie/therapie-der-migraneattacke-und-prophylaxe-dermigrane-2022
• 2 Ornello R, Caponnetto V, Ahmed F. et al. Evidence-based guidelines for the pharmacological treatment of migraine, summary version. Cephalalgia 2025; 45: 3331024251321500
• 3 Ornello R, Caponnetto V, Ahmed F. et al. Evidence-based guidelines for the pharmacological treatment of migraine. Cephalalgia 2025; 45: 3331024241305381
• 4 Puledda F, Sacco S, Diener HC. et al. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine. Cephalalgia 2024; 44: 3331024241269735
• 5 May A, Schulte LH. Chronic migraine: risk factors, mechanisms and treatment. Nat Rev Neurol 2016; 12: 455-464
• 6 Barbanti P, Aurilia C, Egeo G. et al. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. J Neurol 2024; 271: 2434-2443
• 7 Diener HC, Bussone G, van Oene JC. et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814-823
• 8 Serrano D, Lipton RB, Scher AI. et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 2017; 18: 101
• 9 Wang X, Wen D, He Q. et al. Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. J Headache Pain 2022; 23: 105
• 10 Vries Lentsch S, Verhagen IE, van den Hoek TC. et al. Treatment with the monoclonal calcitonin gene-related peptide receptor antibody erenumab: A real-life study. Eur J Neurol 2021; 28: 4194-4203
• 11 Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 2014; 20: 22-33
• 12 Hepp Z, Dodick DW, Varon SF. et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 2015; 35: 478-488
• 13 Silberstein SD, Dodick DW, Lindblad AS. et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology 2012; 78: 976-984
• 14 Domingues RB, Silva AL, Domingues SA. et al. A double-blind randomized controlled trial of low doses of propranolol, nortriptyline, and the combination of propranolol and nortriptyline for the preventive treatment of migraine. Arq Neuropsiquiatr 2009; 67: 973-977
• 15 Mullin K, Kudrow D, Croop R. et al. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 2020; 94: e2121-e2125
• 16 Alsaadi T, Suliman R, Santos V. et al. Safety and Tolerability of Combining CGRP Monoclonal Antibodies with Gepants in Patients with Migraine: A Retrospective Study. Neurol Ther 2024; 13: 465-473
• 17 Diener HC, Agosti R, Allais G. et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebocontrolled trial. Lancet Neurol 2007; 6: 1054-1062
• 18 Alpuente A, Gallardo VJ, Caronna E. et al. In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain 2021; 22: 151
• 19 American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache 2019; 59: 1-18
• 20 Wober C, Woberbingol C, Koch G. et al. Long-Term Results of Migraine Prophylaxis With Flunarizine and Beta-Blockers. Cephalalgia 1991; 11: 251-256
• 21 Romero Del Rincón C, Gonzalez-Martinez A, Quintas S. et al. RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine. Eur J Neurol 2024; 31: e16203
• 22 Versijpt J, Paemeleire K, Reuter U. et al. Calcitonin generelated peptide-targeted therapy in migraine: current role and future perspectives. Lancet 2025; 405: 1014-1026
• 23 Caponnetto V, Deodato M, Robotti M. et al. Comorbidities of primary headache disorders: a literature review with metaanalysis. J Headache Pain 2021; 22: 71
• 24 Buse DC, Reed ML, Fanning KM. et al. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain 2020; 21: 23
• 25 Vries Lentsch S, van der Arend BWH. de BoerI. et al. Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine. Eur J Neurol 2024; 31: e16106
• 26 Smitherman TA, Tietjen GE, Schuh K. et al. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies. Headache 2020; 60: 2202-2219
• 27 Silberstein SD, Ben-Menachem E, Shank RP. et al. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther 2005; 27: 154-165
• 28 Dodick DW, Turkel CC, DeGryse RE. et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-936
• 29 Aurora SK, Dodick DW, Turkel CC. et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803
• 30 Goadsby PJ, Friedman DI, Holle-Lee D. et al. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial. Neurology 2024; 103: e209584
• 31 Haghdoost F, Puledda F, Garcia-Azorin D. et al. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials. Cephalalgia 2023; 43: 03331024231159366
• 32 Giri S, Tronvik E, Linde M. et al. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis. Cephalalgia 2023; 43: 3331024231156922
• 33 Vikelis M, Rikos D, Argyriou AA. et al. Switching between anti-CGRP monoclonal antibodies in migraine prophylaxis. Expert Rev Neurother 2025; 5: 1-16
• 34 Romozzi M, Munafò A, Burgalassi A. et al. Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review. Headache: J Head Face Pain 2025; 65: 342-352
• 35 Barbanti P, Egeo G, Pistoia F. et al. GIANT: a prospective, multicenter, real-world study on the effectiveness, safety, and tolerability of atogepant in migraine patients with multiple therapeutic failures. J Headache Pain 2025; 26: 122
• 36 Smirnoff L, Bravo M, Hyppolite T. Neuromodulation for Headache Management in Pregnancy. Curr Pain Headache Rep 2025; 29: 14
• 37 Wong HT, Khan R, Buture A. et al. OnabotulinumtoxinA treatment for chronic migraine in pregnancy: An updated report of real-world headache and pregnancy outcomes over 14 years in Hull. Cephalalgia 2025; 45: 3331024251327387
• 38 Hugger SS, Do TP, Ashina H. et al. Migraine in older adults. Lancet Neurol 2023; 22: 934-945
• 39 Diener HC, Antonaci F, Braschinsky M. et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol 2020; 27: 1102-1116
• 40 Scheffler A, Basten J, Menzel L. et al. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache – a retrospective real-world analysis. J Headache Pain 2024; 25: 109
• 41 Turkel CC, Aurora S, Diener HC. et al. Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore) 2023; 102: e32600
• 42 Diener HC, Rizzoli P. Chronic migraine and medication overuse. Handb Clin Neurol 2023; 198: 187-200